InsiderTrades.com logo
Michael J. Rossi net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Michael Rossi Biography and Net Worth

CEO of Y-mAbs Therapeutics

Michael Rossi has more than 30 years of radiopharmaceutical, drug development, commercialization and people leadership experience on a global scale, most recently as President, Medical Group at Mirion. Before Mirion, Michael served as the Head of Radioligand Imaging for AAA, a Novartis Company. Michael also spent five years at Jubilant Pharma, where he served in several different roles including President of Jubilant Radiopharma, and brings experience from GE Healthcare, Tyco Healthcare/Mallinckrodt and Syncor International. Michael earned a Bachelor of Science in Pharmacy from the University of the Sciences in Philadelphia and holds an Authorized Nuclear Pharmacist Certification from Butler University. He has served on several boards of directors and remains a Licensed Pharmacist in the state of Pennsylvania.

What is Michael J. Rossi's net worth?

The estimated net worth of Michael J. Rossi is at least $1.18 million as of March 7th, 2025. Mr. Rossi owns 137,083 shares of Y-mAbs Therapeutics stock worth more than $1,180,285 as of April 30th. This net worth approximation does not reflect any other assets that Mr. Rossi may own. Learn More about Michael J. Rossi's net worth.

How do I contact Michael J. Rossi?

The corporate mailing address for Mr. Rossi and other Y-mAbs Therapeutics executives is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. Y-mAbs Therapeutics can also be reached via phone at (646) 885-8505 and via email at [email protected]. Learn More on Michael J. Rossi's contact information.

Has Michael J. Rossi been buying or selling shares of Y-mAbs Therapeutics?

Michael J. Rossi has not been actively trading shares of Y-mAbs Therapeutics in the last ninety days. Most recently, Michael J. Rossi sold 3,917 shares of the business's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.20, for a transaction totalling $20,368.40. Following the completion of the sale, the chief executive officer now directly owns 137,083 shares of the company's stock, valued at $712,831.60. Learn More on Michael J. Rossi's trading history.

Who are Y-mAbs Therapeutics' active insiders?

Y-mAbs Therapeutics' insider roster includes Thomas Gad (Insider), Jorris Jan Wilms (Sr. VP & COO ), Bo Kruse (CFO), Vignesh Rajah (CMO), Michael Rossi (CEO), Johan Wedell-Wedellsborg (Director), and Joris Wilms (COO). Learn More on Y-mAbs Therapeutics' active insiders.

Michael J. Rossi Insider Trading History at Y-mAbs Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2025Sell3,917$5.20$20,368.40137,083View SEC Filing Icon  
See Full Table

Michael J. Rossi Buying and Selling Activity at Y-mAbs Therapeutics

This chart shows Michael J Rossi's buying and selling at Y-mAbs Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Y-mAbs Therapeutics Company Overview

Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $8.61
Low: $8.61
High: $8.61

50 Day Range

MA: $8.58
Low: $8.51
High: $8.61

2 Week Range

Now: $8.61
Low: $3.55
High: $8.61

Volume

N/A

Average Volume

637,200 shs

Market Capitalization

$391.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.54